UUFlexExecutive Cockpit
← Back to Board
Use “Save as PDF” in the print dialog
UUFlex · Executive Cockpit

Board Pack

Value creation, performance and risk review — FY26 (Mar'26, audited consolidated anchor). Packaging Films (incl. PET chips) · Flexible Packaging, Aseptic & Holography · Chemicals & Inks · Engineering & Cylinders.

₹15,401 Cr
Revenue (FY26 audited)
8
Growth & capex initiatives
12,000+
Employees · 9 plant countries
India's largest multinational flexible-packaging & solutions company
Market position
Listed (NSE: UFLEX · BSE: 500148) · promoters 44.58% · pledge nil (released FY26) · Ashok Chaturvedi (Chairman & Managing Director, founder) · Arun Kumar Sharma (President F&A & Group CFO — since 10 Jul 2026) · HQ Noida, Uttar Pradesh (NCR)
Where we stand

Executive scorecard

UFlex · Board Pack · 1 · Executive Summary
Revenue from Operations
₹15,401 Cr
prior ₹15,036 Cr
Revenue Growth (YoY)
2.4%
prior 12.5%
EBITDA (Reported)
₹1,984 Cr
prior ₹1,834 Cr
EBITDA Margin (Reported)
12.8%
prior 12.1%
Value-Added & Converting Revenue
₹5,069 Cr
prior ₹4,295 Cr
Value-Added & Converting Mix
33.0%
prior 28.6%
CPG Account Net Revenue Retention
104.0%
prior 101.0%
Employees (Global)
12,000
prior 12,000
Executive summary
Growth & profitability

Revenue, EBITDA & mix

UFlex · Board Pack · 2 · Performance
Revenue by segment
Packaging Films (incl. PET chips)59%
Flexible Packaging, Aseptic & Holography33%
Chemicals & Inks5%
Engineering & Cylinders3%
Packaging Films (incl. PET chips)
₹9,093 Cr
-3.9% · EBITDA ~10.5% · Val-add 18%
Flexible Packaging, Aseptic & Holography
₹5,069 Cr
+18% · EBITDA ~16.5% · Val-add 78%
Chemicals & Inks
₹791 Cr
-9.6% · EBITDA ~13% · Val-add 55%
Engineering & Cylinders
₹448 Cr
+11% · EBITDA ~12% · Val-add 45%
Mix-shift validation

Line & brand economics, margin journey

UFlex · Board Pack · 3 · Operating Lines
Line / brandEstablishedRevenueContracted / value-addedEBITDA (modeled)Program captureStatus
Flexible Packaging (Laminates & Pouches)1988₹3,389 Cr₹3,100 Cr₹542 Cr84%Integrated
Flex Films (Global Films)1994₹9,093 Cr₹480 Cr₹955 Cr78%Integrated
UFlex Engineering & Cylinders1995₹448 Cr₹0 Cr₹54 Cr70%In progress
UFlex Holography & Security1999₹380 Cr₹380 Cr₹68 Cr80%Integrated
Flexcure / Flexgreen (Chemicals & Inks)2004₹791 Cr₹0 Cr₹103 Cr72%In progress
Asepto (Aseptic Liquid Packaging)2017₹1,300 Cr₹1,300 Cr₹234 Cr76%In progress
F-TPM / F-WSP (Specialty Films)2019₹420 Cr₹139 Cr₹71 Cr66%In progress
Asclepius (90% PCR Film)2023₹240 Cr₹150 Cr₹34 Cr58%In progress

Global films and the converting book carry the base; the value engines (Asepto aseptic, holography, Asclepius 90% PCR, F-TPM / F-WSP specialty) remain in scale-up and program capture. Lines are overlapping lenses — revenue and EBITDA are not additive to the group total; EBITDA contribution and Asepto revenue (~₹1,300 Cr) are modeled.

Balance sheet & liquidity

Leverage, cash & covenants

UFlex · Board Pack · 4 · Capital & Cash
Net Debt / EBITDA
4.3x
target 3.0x
Covenant Headroom
1.1x
target 2.5x
DSCR (EBITDA / Debt Service)
1.4x
target 1.8x
Cash & Equivalents
₹1,231 Cr
Operating Cash Flow
₹992 Cr
target ₹1,200 Cr
Cash Conversion Cycle
125d
target 105d
DSO (Days Sales Outstanding)
92d
target 75d
Program Realization (Mix / Circularity / WC)
68.0%
target 100.0%
Net leverage 4.3x (net debt ₹8,622 Cr) is ELEVATED — it rose from 3.73× through the ₹2,044 Cr capex cycle (peak 4.52× in Q3), leaving ~1.15× headroom to the modeled 5.5× ceiling — with ₹1,231 Cr of cash on hand and interest cover ~2.55×. The path: FY27 volume on commissioned assets (Egypt aseptic, chips, Mexico), capex moderation, working-capital release (CCC 125d, DSO 92→75) and the value-added mix — deleverage is the goal, not the achievement.
Governance

Watch-list & priority actions

UFlex · Board Pack · 5 · Risk & Actions
●Commodity-films drag on the coreceo
Packaging Films ₹9,093 Cr (−3.9% YoY) on the ~260 KT India BOPET glut; India films utilization 72.3%.
→ Shift mix to Alox / high-barrier / PCR and push chips third-party volume; hold share, don't chase price.
●Value-added engine compoundingceo
Flexible Packaging, Aseptic & Holography at ₹5,069 Cr (+18.0%) — 33% of revenue; Asepto sold 7.97 bn packs.
→ Commission Egypt aseptic (24 bn packs total) and convert the CPG whitespace — mix 33%→40% is the re-rating fuel.
●Leverage rose through the capex cyclecfo
Net debt ₹8,622 Cr = 4.35× EBITDA, up from 3.73× (peak 4.52× in Q3); headroom to the 5.5× ceiling is ~1.15×.
→ Hold FY27 capex ≤ ₹1,400 Cr, sweep OCF to debt as commissioned assets ramp — deleverage is the goal, not the achievement.
●Working capital is heavycfo
DSO 92 days, inventory ~97 days; AR ₹3,882 Cr with ₹700 Cr >60d overdue.
→ Tighten CPG terms & export-doc cycles; factor overseas receivables selectively; target DSO 75.
●Q4 exit margin 15.3% — 14-quarter highcfo
Q4 EBITDA ₹627 Cr at 15.3% (revenue ₹4,097 Cr, +5.7%); normalized PAT ₹203 Cr (+105.5%).
→ Quote it as an EXIT rate, not run-rate — lock the recovery via value-added contracts entering FY27.
●FX & geopolitical exposureboard
USD/INR averaged 85.4 (Q1) → 91.7 (Q4), closing 94.65; Russia/CIS plant (48 kTPA) operating; West Asia conflict freight risk.
→ Natural-hedge via exports, review CIS repatriation quarterly, disclose devaluation sensitivity (FY25 took ₹178 Cr exceptional).
●Deep-value re-rating case intactboard
Market cap ₹3,416 Cr = 0.22× sales / 0.42× book vs EPL at 2× the mcap on ⅓ the revenue — the market prices leverage + cyclicality.
→ Deleverage + Asepto scale + margin recovery are the equity torque; keep dividend (₹3/sh) and pledge at nil.
●₹2,044 Cr capex must convert to volumeboard
Egypt aseptic (USD 126 mn) near commissioning; Dharwad BOPP ₹715 Cr FY28; Mexico WPP in validation; CWIP ₹2,169 Cr.
→ Track commissioning milestones monthly — FY27 volume-led growth is the deleverage plan's engine.
Material external signals
[BSE/NSE] Q4 FY26 results: EBITDA margin 15.3% — highest in 14 quarters; FY27 guided above FY26 · UFlex Limited→ exit rate, not run-rate — recovery evidence for the re-rating case
[News] India BOPET overcapacity ~260 KT keeps commodity film spreads thin · Packaging Films (incl. PET chips)→ films −3.9% YoY; value-added mix (Alox / PCR / aseptic) is the mitigation
[News] EPR recycled-content mandates in force (30% rigid / 10% flexible / 5% MLP) — rPET demand tailwind · Asclepius (90% PCR Film)→ Noida 36 kTPA rPET + Asclepius 90% PCR film ride the compliance wave
[News] West Asia conflict (from 28 Feb 2026) disrupts Hormuz petchem flows — MEG / PP / freight cost-push · PET resin & chips inputs — PTA / MEG (crude-linked)→ Q4 cost-push on resin & freight; watch pass-through lags in CPG contracts

UFlex is listed (NSE: UFLEX · BSE: 500148): headline financials are real FY26 audited consolidated anchors (PAT signed: +₹317 Cr vs −₹691 Cr FY24 trough); granular per-line / per-program detail is modelled. AI summary generated by Azure OpenAI (GPT-4.1).